'''拟抗体'''是一种功能与[[抗体|抗体]]类似，但结构与之完全没有任何关系的[[有机化合物|有机化合物]]，它可以与[[抗原|抗原]]特异结合。通常它是人造的[[肽|肽]]或者[[蛋白质|蛋白质]]，[[摩尔质量|摩尔质量]]介于3至20[[kDa|kDa]]之间。有些[[氨基酸|氨基酸]]和[[小分子|小分子]]也被认为是拟抗体，而不是人造抗体、[[抗体结合区段|抗体结合区段]]或者[[融合蛋白|融合蛋白]]的一部分。某些拟抗体具有和抗体类似的[[β折叠|β折叠]]结构。拟抗体相对于抗体来说，通常都具有更好的[[溶解性|溶解性]]，组织穿透能力，更好的热稳定性和酶稳定性，以及相对较低的生产成本。拟抗体正被开发用于[[疗法|治疗]]与[[诊断|医学诊断]]上<ref>{{cite journal |author=Gebauer M, Skerra A |title=Engineered protein scaffolds as next-generation antibody therapeutics |journal=Curr Opin Chem Biol |volume=13 |issue=3 |pages=245–255 |pmid=19501012 |doi=10.1016/j.cbpa.2009.04.627 |url=http://linkinghub.elsevier.com/retrieve/pii/S1367-5931(09)00068-4 |date=June 2009 |access-date=2011-09-14 |archive-date=2019-11-29 |archive-url=https://web.archive.org/web/20191129080814/https://linkinghub.elsevier.com/retrieve/pii/S1367-5931(09)00068-4 |dead-url=no }}</ref>。

==示例==
{| class="wikitable"
! 类型
! 原型
! 分子量
! 药品举例
|-
| [[亲和配体分子|亲和配体分子]]<ref name="pmid18435759">{{cite journal |author=Nygren PA |title=Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold |journal=FEBS J. |volume=275 |issue=11 |pages=2668–76 |pmid=18435759 |doi=10.1111/j.1742-4658.2008.06438.x |date=June 2008}}</ref> || [[A蛋白|A蛋白]]Z域 || align="right" | 6 kDa || ABY-025
|-
| rowspan="2" | [[Affilin|Affilin]]<ref>{{cite journal |author=Ebersbach H, Fiedler E, Scheuermann T, ''et al.'' |title=Affilin-novel binding molecules based on human gamma-B-crystallin, an all beta-sheet protein |journal=J. Mol. Biol. |volume=372 |issue=1 |pages=172–85 |pmid=17628592 |doi=10.1016/j.jmb.2007.06.045 |url=|date=September 2007}}</ref>
| [[乙型γ晶状体蛋白|乙型γ晶状体蛋白]] || align="right" | 20 kDa ||
|-
| [[泛素|泛素]] || align="right" | 10 kDa || SPVF 2801
|-
| [[Affitin|Affitin]]<ref name="pmid18822295">{{cite journal |author=Krehenbrink M, Chami M, Guilvout I, Alzari PM, Pécorari F, Pugsley AP |title=Artificial binding proteins (Affitins) as probes for conformational changes in secretin PulD |journal=J. Mol. Biol. |volume=383 |issue=5 |pages=1058–68 |pmid=18822295 |doi=10.1016/j.jmb.2008.09.016 |url=http://linkinghub.elsevier.com/retrieve/pii/S0022-2836(08)01117-0 |date=November 2008 |access-date=2011-09-14 |archive-date=2019-11-30 |archive-url=https://web.archive.org/web/20191130155724/https://linkinghub.elsevier.com/retrieve/pii/S0022-2836(08)01117-0 |dead-url=no }}</ref> ||[[Sac7d|Sac7d]] (from ''[[Sulfolobus|Sulfolobus]] acidocaldarius'') || align="right" | 7 kDa ||
|-
| [[载脂蛋白拟抗体|载脂蛋白拟抗体]]<ref name="pmid18435758">{{cite journal |author=Skerra A |title=Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities |journal=FEBS J. |volume=275 |issue=11 |pages=2677–83 |pmid=18435758 |doi=10.1111/j.1742-4658.2008.06439.x |date=June 2008}}</ref> ||[[Lipocalin|Lipocalin]]s || align="right" | 20 kDa ||
|-
| [[亲和性多聚体|亲和性多聚体]]<ref name="pmid16299519">{{cite journal |author=Silverman J, Liu Q, Lu Q, ''et al.'' |title=Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains |journal=Nat. Biotechnol. |volume=23 |issue=12 |pages=1556–61 |pmid=16299519 |doi=10.1038/nbt1166 |url=|date=December 2005}}</ref> || A [[Protein_domain|domains]] of various membrane receptors || align="right" | 9–18 kDa ||
|-
| [[人造锚重复蛋白|人造锚重复蛋白]]<ref name="pmid18621567">{{cite journal |author=Stumpp MT, Binz HK, Amstutz P |title=DARPins: a new generation of protein therapeutics |journal=Drug Discov. Today |volume=13 |issue=15–16 |pages=695–701 |pmid=18621567 |doi=10.1016/j.drudis.2008.04.013 |url=http://linkinghub.elsevier.com/retrieve/pii/S1359-6446(08)00162-1 |date=August 2008 |access-date=2011-09-14 |archive-date=2019-12-01 |archive-url=https://web.archive.org/web/20191201004337/https://linkinghub.elsevier.com/retrieve/pii/S1359-6446(08)00162-1 |dead-url=no }}</ref> || [[Ankyrin_repeat|Ankyrin repeat]] motif || align="right" | 10–19 kDa || MP0112
|-
| [[原癌基因酪氨酸蛋白激酶多聚体|原癌基因酪氨酸蛋白激酶多聚体]]<ref name="PMID: 17130124">{{cite journal |author=Grabulovski D |title=A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties |journal=J Biol Chem |volume=282 |issue=5 |pages=3196–3204 |year=2007 |pmid=17130124 |last2=Kaspar |first2=M |last3=Neri |first3=D |doi=10.1074/jbc.M609211200 }}</ref> || [[原癌基因酪氨酸蛋白激酶|原癌基因酪氨酸蛋白激酶]]的[[SH3|SH3]]域 || align="right" | 7 kDa ||
|-
| [[Kunitz型结构域肽|Kunitz型结构域肽]]<ref name="pmid16566296">{{cite journal |author=Nixon AE, Wood CR |title=Engineered protein inhibitors of proteases |journal=Curr Opin Drug Discov Devel |volume=9 |issue=2 |pages=261–8 |pmid=16566296 |date=March 2006}}</ref> || 多种[[蛋白酶抑制剂|蛋白酶抑制剂]]的Kunitz域 || align="right" | 6 kDa || [[Ecallantide|Ecallantide]]
|-
| [[单拟抗体|单拟抗体]]<ref name="pmid17041261">{{cite journal |author=Koide A, Koide S |title=Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain |journal=Methods Mol. Biol. |volume=352 |pages=95–109 |year=2007 |pmid=17041261 }}</ref> || [[纤维连接蛋白|纤维连接蛋白]]的第10个[[纤维连接蛋白3型域|3型域]]|| align="right" | 10 kDa || [[Angiocept|Angiocept]]
|}

== 引用 ==
{{reflist|2}}

{{Engineered antibodies}}

[[Category:分子生物学|Category:分子生物学]]